MedicalResearch.com Interview with:
Simon Portsmouth, MD
Senior Medical Director
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Antibiotics for multidrug resistant Gram-negative infections are desperately needed. Cefiderocol is the first siderophore antibiotic to reach patients.
Siderophore antibiotics bind to free iron and use the bacterial active iron transport channels to cross the outer membrane of Gram-negative bacteria. Laboratory studies have shown that cefiderocol is active against multi-drug resistant Gram-negative bacteria, often where no other antibiotics are active. It is able to overcome most types of antibiotic resistance due to its active transport into cells and stability against all carbapenemases.
The need for antibiotics for carbapenem resistant Gram-negative infections is described as a critical need by the WHO. This trial was the first in humans with serious infections and demonstrated excellent efficacy in a complicated patient population where almost ¼ were over 75 years of age. Additionally cefiderocol did not appear to have any safety problems, and was well tolerated.
MedicalResearch.com: What should readers take away from your report?
Response: Antibiotics for the most serious drug resistant bacteria are being developed and this points to a potential treatment where no other active antibiotics may exist.
Clinical development of this antibiotic is continuing.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: Trials are ongoing in hospital acquired pneumonia and carbepenem resistant infections. These will give further information about the utility of cefiderocol in these areas of unmet need.
Disclosures, I am an employee of Shionogi Inc.
Simon Portsmouth, David van Veenhuyzen, Roger Echols, Mitsuaki Machida, Juan Camilo Arjona Ferreira, Mari Ariyasu, Peter Tenke, Tsutae Den Nagata. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. The Lancet Infectious Diseases, 2018; DOI: 10.1016/S1473-3099(18)30554-1
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.